DB
KZIA

Dmitry Balyasny’s Kazia Therapeutics KZIA Stock Holding History

Dmitry Balyasny’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-193,114
Closed -$1.44M – 3283
2026
Q1 		$1.44M Buy
+193,114
New +$1.34M ﹤0.01% 1931

Other funds holding KZIA

BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Dmitry Balyasny's KZIA Position: Q2 2026 in Review

Dmitry Balyasny sold out of Kazia Therapeutics (KZIA) in Q2 2026, closing a stake of 193,114 shares — an estimated $1.44M sold.

Dmitry Balyasny first reported a position in KZIA in Q1 2026 and held it in 1 quarter. The position peaked at $1.44M in Q1 2026. 36 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

  • Dmitry Balyasny reported no remaining Kazia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 193,114 Kazia Therapeutics shares in Q2 2026, an estimated $1.44M.
  • Dmitry Balyasny first reported a position in Kazia Therapeutics in Q1 2026 and held it in 1 quarter.
  • Dmitry Balyasny's Kazia Therapeutics position peaked at $1.44M in Q1 2026.
  • 36 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.